Abstract: A barrier system is provided for use in reducing infections associated with post-operative surgical incision and/or a percutaneous medical device, such as a catheter, that is disposed within the surgical incision. Such a barrier system may include: a barrier device having a skin-contacting surface and a catheter-receiving surface; and an adhesive composition configured for adhering to skin, the barrier device, and/or the catheter so as to form a barrier at or adjacent to an incision in the skin where the catheter is percutaneously inserted through the skin. A tensioning anchor and associated system of two or more tensioning anchors is provided for post-operative wound closure. A method for applying and removing the barrier device and tensioning anchors is also provided.

Abstract: A non-human organism for upgrading intermediate oxidation products formed by catalytic degradation of alkanes or polystyrenes is provided. The non-human organism is genetically modified to convert the intermediate oxidation products to secondary metabolites, and in particular to include a positive feedback loop construction in the promotor system. A method includes steps of catalytically degrading alkanes or polystyrene in an oxidizing environment to form intermediate products with one or more catalysts and contacting the intermediate products with the non-human organism such that intermediate oxidation products are converted to secondary metabolites.

Abstract: Haloalkane sulfonic acids and salts thereof are provided. In embodiments, a haloalkane sulfonic acid or salt thereof comprises an alkyl group, at least one sulfonic acid group, and one or more halogens selected from Cl, Br, I, and F, the haloalkane sulfonic acid having a total number of carbon atoms of from 2 to 9, and wherein if at least one F atom is present, the haloalkane sulfonic acid comprises at least one other halogen selected from Cl, Br, and I. Methods of making and using the haloalkane sulfonic acids/salts are also provided.

Abstract: The present disclosure provides conjugates, methods of making the same, and uses thereof. The conjugates of the present technology are useful in inducing anergy in insulin-binding B cells.

Abstract: The disclosure of a compound of Formula I or a pharmaceutically acceptable salt thereof The variables W, R1, R2, R3, and R4 are defined in the disclosure. The disclosure provides a compound or salt of Formula I together with a pharmaceutically acceptable carrier. The disclosure also provides methods of treating a patient for Parkinson's disease and related syndromes, dyskinesia, especially dyskinesias secondary to treating Parkinson's disease with L-DOPA, neurodegenerative disorders such as Alzheimer's disease and dementia, Huntington's disease, restless legs syndrome, bipolar disorder and depression, schizophrenia, cognitive dysfunction, or substance use disorders, the methods comprising administering a compound of Formula I or salt thereof to the patient. The disclosure provides combination methods of treatment in which the compound of Formula I is administered to the patient together with one or more additional active agents.

Abstract: Aerial vehicles, their structures and methods of locomotion are described. An aerial vehicle may include a fuselage having an x-axis, a plurality of flexible structures emanating from the fuselage that take the form of a feather, wing and/or tentacle, at least one motor, and at least one propeller driven by one or more motors. Each flexible structure may extend from a fuselage in any direction and are used to enhance the observability of the aircraft by moving and/or oscillating within a frequency band and at a magnitude that is more easily observed by and catches the human eye.

Abstract: A method of evaluating a cerebrovascular health of a patient includes causing a patient to exercise for an exercise duration at an exercise intensity, collecting cerebrovascular information from the patient during the exercise duration, collecting cardiovascular information from the patient during the exercise duration, correlating the cerebrovascular information to the cardiovascular information to create a correlated cerebrovascular curve, and determining a cerebrovascular health and viability for cerebrovascular therapy.

Abstract: A method of treating amyotrophic lateral sclerosis (ALS) is provided to extend life expectancy in a subject. The method can include administering the ketamine to a subject having ALS such that the subject has an extended life expectancy compared to life expectancy of the subject prior to being administered the ketamine. The extended life expectancy is determined by the subject having a first progression rate of ALS prior to being administered ketamine and a second progression rate of ALS after being administered ketamine. The first progression rate is faster than the second progression rate such that the progression of ALS in the subject is slowed by the ketamine.

Abstract: The present application relates to stacked piezoelectric energy harvesters that include compliant layers between piezoelectric layers. The energy harvesters are useful in various structures and devices, including tissue-stimulating implants, such as spinal fusion implants. The present application also relates to methods of increasing the power output of a piezoelectric energy harvester through the inclusion of compliant layers.

Abstract: This disclosure generally relates to aerial vehicles that may convert from hover-mode to missile-mode flight and back via body tilt for efficient flight and can strike wires such that neither the wires nor the aircraft are damaged, and divergence is prevented. This includes an aerial vehicle having an elongate fuselage having a nose tip, a plurality of engines connected to the fuselage, and at least three protective members connected substantially near the nose tip of the fuselage longitudinally beyond the plurality of engines.

Abstract: Disclosed are pharmaceutical formulations comprising a compound of formula (I): in which R1, R2, R3, and R4 are as described herein, or a pharmaceutically acceptable salt thereof. Also provided are methods for treating pancreatic adenocarcinoma comprising administration of a compound of formula (I), or a pharmaceutically acceptable salt thereof, and methods of detecting the change in expression levels of one or both of FoxA1 and FoxO6 in a pancreatic adenocarcinoma tumor sample from a mammal, wherein the mammal has been administered a compound of formula (I), or a pharmaceutically acceptable salt thereof.

Abstract: Self-healable, omniphobic coatings and related methods are provided. In embodiments, a self-healable, omniphobic coating comprises a matrix of crosslinked, entangled hydrogel polymers, the hydrogel polymers comprising hydroxyl (OH) groups, hydroxyl group precursors, or both, and nanoparticles distributed throughout the matrix; and fluorinated silane molecules covalently bound to the matrix.

Abstract: The present disclosure relates to devices and methods for delivery of a ferrofluid to a targeted treatment site, such as delivery of a ferroadhesive to a pathological fistula to occlude the fistula. A device includes a catheter having a lumen and a distal opening. A hollow solenoid is coupled to a distal section of the catheter, and a hollow core of the solenoid allows passage of a ferrofluid through the catheter and through the hollow core so that it may exit past the distal end of the hollow solenoid. The solenoid may be selectively actuated to maintain or control the position of the delivered ferrofluid.

Abstract: A medical imaging support includes a substantially flat radiotransparent platform, a plurality of radiotransparent flaps, and closure mechanisms. The platform has a longitudinal direction between a top edge and a bottom edge. The plurality of sets of radiotransparent flaps have a first set of the radiotransparent flaps positioned closer to the top edge in the longitudinal direction than the second set of radiotransparent flaps, and at least one set of flaps includes a first flap and a second flap where the first flap is fixed to the platform proximate a first side edge and the second flap is fixed to the platform proximate a second side edge. The closure mechanisms are positioned on the first flap or second flap of each set of radiotransparent flaps, wherein the closure mechanism selectively fixes the first flap to the second flap of each set of radiotransparent flaps.

Abstract: In one example, mobile industrial equipment for coupling to a truck for on highway transportation is provided. The mobile industrial equipment includes a frame to connect to the truck, a plurality of wheels connected to the frame, and a track assembly connected to the frame. In another example a method for using mobile equipment is provided. The method includes transporting mobile industrial equipment over the highway with a plurality of wheels connected to a frame of the mobile industrial equipment. The frame of the mobile industrial equipment is separated from the truck. The mobile industrial equipment is moved while separated from the truck using a track connected to the frame of the mobile industrial equipment.

Abstract: Disclosed herein are olfactory diagnostic kits and methods for screening for an olfactory dysfunction. Also disclosed are olfactory training kits and methods for treating an olfactory dysfunction in a subject. Also disclosed is a method for diagnosing a subject for an olfactory dysfunction. Also disclosed is a method for training a subject with an olfactory dysfunction.

Abstract: A remote psychotherapy system includes an environment. A patient selects a patient avatar. The patient provides input for a provider avatar, which may be influenced by one or more Jungian archetypes. The patient wears a virtual reality simulator having a head mounted device. The virtual reality simulator includes a sensor that collects biofeedback information. The biofeedback information is used to determine state information about the patient, such as an emotional state of the user. The state information and/or the biofeedback information is transmitted to the provider and presented to the provider in a graphical user interface (GUI) on a provider virtual reality device.

Abstract: Methods for recovering a metal from a metal-containing material are provided. In embodiments, such a method comprises exposing a metal-containing material to a leaching solution comprising a solvent and a binoxalate, a tetraoxalate, or a combination thereof, under conditions to provide a leachate comprising a soluble metal oxalate; inducing precipitation of a metal-containing precipitate comprising the metal of the soluble metal oxalate from the leachate; and recovering the metal-containing precipitate.